NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Innate Pharma SA IPHA
9 fiscal years on record · EUR · FY2025 reported · SEC filings only
Growth
EUR 9.0M
Revenue, FY2025 · full 9-year series below
Revenue €M
Net income €M
FY2025 · Revenue 9.0 · Net income -49.2
Compound annual growth
Revenue compounded at −33.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−546 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -599.8% · Net -546.1%
ROE
Not available in our data for this period.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · EUR
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue €B | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
| Operating income €B | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| EBITDA €B | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Income tax €B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Net income €B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 | −0.0 |
| Free cash flow €B | −0.1 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | 0.0 | −0.0 | −0.1 |
| EPS, diluted € | −0.55 | −0.61 | −0.09 | −0.73 | −0.66 | −0.81 | −0.31 | 0.05 | −0.89 |
| Dividend / sh € | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · |
| Shares out B | · | · | · | 0.08 | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED
Reconciled in 9 of 19 fiscal years. 40 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
Data on record since2017